View ValuationWest Pharmaceutical Services 将来の成長Future 基準チェック /26West Pharmaceutical Services利益と収益がそれぞれ年間10.2%と6.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.5% 10.2%なると予測されています。主要情報10.2%収益成長率10.20%EPS成長率Life Sciences 収益成長20.2%収益成長率6.1%将来の株主資本利益率18.54%アナリストカバレッジGood最終更新日20 May 2026今後の成長に関する最新情報お知らせ • Apr 23+ 1 more updateWest Pharmaceutical Services, Inc. Provides Earnings Guidance for the Second Quarter 2026West Pharmaceutical Services, Inc. provided earnings guidance for the second quarter 2026. For the period, it is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million. Reported net sales growth anticipated to be in the range of 8.3% to 10.9%.お知らせ • Feb 12West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026West Pharmaceutical Services, Inc. provided first quarter and full year 2026 guidance. First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%. Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%. Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates.お知らせ • Oct 23+ 1 more updateWest Pharmaceutical Services, Inc. Revises Earnings Guidance for the Full-Year 2025West Pharmaceutical Services, Inc. revised earnings guidance for the Full-Year 2025. For the year, the Company is increasing net sales guidance range to $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion. Reported net sales growth anticipated to be in the range of 5.8% to 6.1%, organic net sales growth is expected to be in the range of 3.75% to 4.0%, up from the previous guidance range of 3.0% to 3.75%. Net sales guidance includes an estimated benefit of approximately $59 million based on current foreign currency exchange rates. Diluted EPS is expected to be $6.75 to $6.80.お知らせ • Jul 24+ 1 more updateWest Pharmaceutical Services, Inc. Increases Earnings Guidance for the Year 2025West Pharmaceutical Services, Inc. increased earnings guidance for the year 2025. The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%. Diluted EPS is expected to be $6.36 to $6.56.すべての更新を表示Recent updatesReported Earnings • Apr 26First quarter 2026 earnings released: EPS: US$1.93 (vs US$1.24 in 1Q 2025)First quarter 2026 results: EPS: US$1.93 (up from US$1.24 in 1Q 2025). Revenue: US$844.9m (up 21% from 1Q 2025). Net income: US$138.8m (up 55% from 1Q 2025). Profit margin: 16% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • Apr 23+ 1 more updateWest Pharmaceutical Services, Inc. Provides Earnings Guidance for the Second Quarter 2026West Pharmaceutical Services, Inc. provided earnings guidance for the second quarter 2026. For the period, it is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million. Reported net sales growth anticipated to be in the range of 8.3% to 10.9%.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €265, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 18x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €186 per share.Board Change • Apr 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Independent Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 09West Pharmaceutical Services, Inc. to Report Q1, 2026 Results on Apr 23, 2026West Pharmaceutical Services, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026お知らせ • Mar 13West Pharmaceutical Services, Inc., Annual General Meeting, May 04, 2026West Pharmaceutical Services, Inc., Annual General Meeting, May 04, 2026.お知らせ • Mar 10+ 1 more updateWest Pharmaceutical Services, Inc. Announces Eric M. Green Plans to Retire as President and Chair of BoardWest Pharmaceutical Services, Inc. announced on March 9, 2026 that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. Green has served as President and Chief Executive Officer of West since April 2015, and he became Chair of the Board in May 2022.Board Change • Feb 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 18+ 1 more updateWest Pharmaceutical Services, Inc. (NYSE:WST) announces an Equity Buyback for $1,000 million worth of its shares.West Pharmaceutical Services, Inc. (NYSE:WST) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its common stock. The repurchase program has no expiration date.お知らせ • Feb 12West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026West Pharmaceutical Services, Inc. provided first quarter and full year 2026 guidance. First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%. Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%. Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates.お知らせ • Jan 29West Pharmaceutical Services, Inc. to Report Q4, 2025 Results on Feb 12, 2026West Pharmaceutical Services, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 12, 2026お知らせ • Dec 10West Pharmaceutical Services, Inc. Declares Regular Quarterly Dividend on Common Stock, Payable on February 4, 2026On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026.お知らせ • Oct 27West Pharmaceutical Services, Inc. Announces the Launch of its West Synchrony Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, GermanyWest Pharmaceutical Services, Inc. announced the launch of its West Synchrony™? Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026. The West Synchrony PFS system delivers a fully verified system-level solution designed specifically for biologics and vaccines. It sets a new standard in drug delivery by accelerating syringe selection through its comprehensive performance and regulatory data packages. Key benefits of the West Synchrony PFS system include: Design and System-Level Performance: a single design verification and characterization package from West ensures the form, fit and function of the entire PFS system. Regulatory Ease with Comprehensive Submission: a streamlined submission process with one system-level drug master file and regulatory package tailored for comprehensive regulatory needs. Single Source Supply: single supplier approach, offering make-to-stock and make-to-order supply with low minimum order quantities, ensuring reliability and flexibility.Reported Earnings • Oct 24Third quarter 2025 earnings released: EPS: US$1.94 (vs US$1.87 in 3Q 2024)Third quarter 2025 results: EPS: US$1.94 (up from US$1.87 in 3Q 2024). Revenue: US$804.6m (up 7.7% from 3Q 2024). Net income: US$140.0m (up 2.9% from 3Q 2024). Profit margin: 17% (in line with 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 23+ 1 more updateWest Pharmaceutical Services, Inc. Revises Earnings Guidance for the Full-Year 2025West Pharmaceutical Services, Inc. revised earnings guidance for the Full-Year 2025. For the year, the Company is increasing net sales guidance range to $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion. Reported net sales growth anticipated to be in the range of 5.8% to 6.1%, organic net sales growth is expected to be in the range of 3.75% to 4.0%, up from the previous guidance range of 3.0% to 3.75%. Net sales guidance includes an estimated benefit of approximately $59 million based on current foreign currency exchange rates. Diluted EPS is expected to be $6.75 to $6.80.お知らせ • Oct 09West Pharmaceutical Services, Inc. to Report Q3, 2025 Results on Oct 23, 2025West Pharmaceutical Services, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025New Risk • Sep 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Board Change • Sep 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 12West Pharmaceutical Services, Inc. Announces Departure of Kimberly Banks Mackay, Senior Vice President, General Counsel, and Corporate Secretary, Effective No Later Than December 31, 2025On September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure continuity and a smooth and orderly transition of responsibilities. Ms. MacKay will continue her current duties until she leaves the Company. The Company extends its gratitude to Ms. MacKay for her exemplary service and contributions during her tenure and wishes her success in her future endeavors.Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 27Second quarter 2025 earnings released: EPS: US$1.83 (vs US$1.53 in 2Q 2024)Second quarter 2025 results: EPS: US$1.83 (up from US$1.53 in 2Q 2024). Revenue: US$766.5m (up 9.2% from 2Q 2024). Net income: US$131.8m (up 18% from 2Q 2024). Profit margin: 17% (up from 16% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €227, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €235 per share.お知らせ • Jul 24+ 1 more updateWest Pharmaceutical Services, Inc. Increases Earnings Guidance for the Year 2025West Pharmaceutical Services, Inc. increased earnings guidance for the year 2025. The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%. Diluted EPS is expected to be $6.36 to $6.56.お知らせ • Jul 22West Pharmaceutical Services, Inc. Announces Appointment of Robert McMahon as Senior Vice President, Effective as of August 4, 2025On July 21, 2025, West Pharmaceutical Services, Inc. Announced the appointment of Robert McMahon as Senior Vice President, effective as of August 4, 2025 (the “Commencement Date”). Mr. McMahon will serve on the Company's senior leadership team and will oversee finance, audit, treasury, tax, investor relations and procurement. Prior to joining West, Mr. McMahon, age 56, served as the Chief Financial Officer of Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. At Agilent, he was responsible for finance, audit, treasury, tax, investor relations, IT and procurement. From 2014 to 2018, Mr. McMahon served as Chief Financial Officer at Hologic, Inc., a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products. Prior to Hologic, Mr. McMahon spent 20 years with Johnson & Johnson in various executive financial roles of increasing responsibility. He has also served as an Independent Director at OraSure Technologies, Inc. since 2023. Mr. McMahon earned his Master of Business Administration from the University of Central Florida and his Bachelor's degree from the University of Florida.お知らせ • Jul 21West Pharmaceutical Services, Inc. Announces CFO Changes, Effective August 4, 2025West Pharmaceutical Services, Inc. announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. Mr. McMahon has been Chief Financial Officer of Agilent Technologies Inc. since 2018. In this role, he is responsible for finance, audit, treasury, tax, investor relations, IT and procurement. Prior to Agilent, Mr. McMahon was the CFO at Hologic, Inc. and spent 20 years with Johnson & Johnson, in executive financial roles of increasing responsibility. He has also served as an Independent Director at OraSure Technologies, Inc. since 2023.お知らせ • Jul 08West Pharmaceutical Services, Inc. to Report Q2, 2025 Results on Jul 24, 2025West Pharmaceutical Services, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 24, 2025お知らせ • Jun 30+ 4 more updatesWest Pharmaceutical Services, Inc.(NYSE:WST) dropped from Russell 1000 Growth-Defensive IndexWest Pharmaceutical Services, Inc.(NYSE:WST) dropped from Russell 1000 Growth-Defensive Index業績と収益の成長予測BIT:1WST - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20283,786771574863812/31/20273,5386905137871412/31/20263,331607446726143/31/20263,221543458715N/A12/31/20253,074494469755N/A9/30/20253,018492379694N/A6/30/20252,960488344677N/A3/31/20252,896467307665N/A12/31/20242,893493276653N/A9/30/20242,876500322702N/A6/30/20242,877525357752N/A3/31/20242,929569386757N/A12/31/20232,950593415777N/A9/30/20232,927559420768N/A6/30/20232,866519397707N/A3/31/20232,884552410711N/A12/31/20222,887586439724N/A9/30/20222,909631388654N/A6/30/20222,929686402675N/A3/31/20222,881684382647N/A12/31/20212,832662331584N/A9/30/20212,681613341572N/A6/30/20212,523519287500N/A3/31/20212,326423307504N/A12/31/20202,147346298473N/A9/30/20202,037312272430N/A6/30/20201,945286277420N/A3/31/20201,888261247377N/A12/31/20191,840242N/A367N/A9/30/20191,792230N/A334N/A6/30/20191,767229N/A314N/A3/31/20191,745219N/A291N/A12/31/20181,717207N/A289N/A9/30/20181,711155N/A297N/A6/30/20181,677151N/A284N/A3/31/20181,627133N/A288N/A12/31/20171,599151N/A263N/A9/30/20171,566190N/A254N/A6/30/20171,544176N/A246N/A3/31/20171,535182N/A237N/A12/31/20161,509144N/A219N/A9/30/20161,487138N/A216N/A6/30/20161,454102N/A216N/A3/31/20161,42685N/A217N/A12/31/20151,40096N/A212N/A9/30/20151,39094N/A190N/A6/30/20151,401123N/A186N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1WSTの予測収益成長率 (年間10.2% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: 1WSTの収益 ( 10.2% ) Italian市場 ( 11.1% ) よりも低い成長が予測されています。高成長収益: 1WSTの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 1WSTの収益 ( 6.1% ) Italian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 1WSTの収益 ( 6.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1WSTの 自己資本利益率 は、3年後には低くなると予測されています ( 18.5 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 21:26終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋West Pharmaceutical Services, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25 アナリスト機関Lawrence MarshBarclaysLuke SergottBarclaysMichael RyskinBofA Global Research22 その他のアナリストを表示
お知らせ • Apr 23+ 1 more updateWest Pharmaceutical Services, Inc. Provides Earnings Guidance for the Second Quarter 2026West Pharmaceutical Services, Inc. provided earnings guidance for the second quarter 2026. For the period, it is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million. Reported net sales growth anticipated to be in the range of 8.3% to 10.9%.
お知らせ • Feb 12West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026West Pharmaceutical Services, Inc. provided first quarter and full year 2026 guidance. First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%. Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%. Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates.
お知らせ • Oct 23+ 1 more updateWest Pharmaceutical Services, Inc. Revises Earnings Guidance for the Full-Year 2025West Pharmaceutical Services, Inc. revised earnings guidance for the Full-Year 2025. For the year, the Company is increasing net sales guidance range to $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion. Reported net sales growth anticipated to be in the range of 5.8% to 6.1%, organic net sales growth is expected to be in the range of 3.75% to 4.0%, up from the previous guidance range of 3.0% to 3.75%. Net sales guidance includes an estimated benefit of approximately $59 million based on current foreign currency exchange rates. Diluted EPS is expected to be $6.75 to $6.80.
お知らせ • Jul 24+ 1 more updateWest Pharmaceutical Services, Inc. Increases Earnings Guidance for the Year 2025West Pharmaceutical Services, Inc. increased earnings guidance for the year 2025. The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%. Diluted EPS is expected to be $6.36 to $6.56.
Reported Earnings • Apr 26First quarter 2026 earnings released: EPS: US$1.93 (vs US$1.24 in 1Q 2025)First quarter 2026 results: EPS: US$1.93 (up from US$1.24 in 1Q 2025). Revenue: US$844.9m (up 21% from 1Q 2025). Net income: US$138.8m (up 55% from 1Q 2025). Profit margin: 16% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • Apr 23+ 1 more updateWest Pharmaceutical Services, Inc. Provides Earnings Guidance for the Second Quarter 2026West Pharmaceutical Services, Inc. provided earnings guidance for the second quarter 2026. For the period, it is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million. Reported net sales growth anticipated to be in the range of 8.3% to 10.9%.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €265, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 18x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €186 per share.
Board Change • Apr 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Independent Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 09West Pharmaceutical Services, Inc. to Report Q1, 2026 Results on Apr 23, 2026West Pharmaceutical Services, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
お知らせ • Mar 13West Pharmaceutical Services, Inc., Annual General Meeting, May 04, 2026West Pharmaceutical Services, Inc., Annual General Meeting, May 04, 2026.
お知らせ • Mar 10+ 1 more updateWest Pharmaceutical Services, Inc. Announces Eric M. Green Plans to Retire as President and Chair of BoardWest Pharmaceutical Services, Inc. announced on March 9, 2026 that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. Green has served as President and Chief Executive Officer of West since April 2015, and he became Chair of the Board in May 2022.
Board Change • Feb 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 18+ 1 more updateWest Pharmaceutical Services, Inc. (NYSE:WST) announces an Equity Buyback for $1,000 million worth of its shares.West Pharmaceutical Services, Inc. (NYSE:WST) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its common stock. The repurchase program has no expiration date.
お知らせ • Feb 12West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026West Pharmaceutical Services, Inc. provided first quarter and full year 2026 guidance. First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%. Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%. Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates.
お知らせ • Jan 29West Pharmaceutical Services, Inc. to Report Q4, 2025 Results on Feb 12, 2026West Pharmaceutical Services, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 12, 2026
お知らせ • Dec 10West Pharmaceutical Services, Inc. Declares Regular Quarterly Dividend on Common Stock, Payable on February 4, 2026On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026.
お知らせ • Oct 27West Pharmaceutical Services, Inc. Announces the Launch of its West Synchrony Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, GermanyWest Pharmaceutical Services, Inc. announced the launch of its West Synchrony™? Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026. The West Synchrony PFS system delivers a fully verified system-level solution designed specifically for biologics and vaccines. It sets a new standard in drug delivery by accelerating syringe selection through its comprehensive performance and regulatory data packages. Key benefits of the West Synchrony PFS system include: Design and System-Level Performance: a single design verification and characterization package from West ensures the form, fit and function of the entire PFS system. Regulatory Ease with Comprehensive Submission: a streamlined submission process with one system-level drug master file and regulatory package tailored for comprehensive regulatory needs. Single Source Supply: single supplier approach, offering make-to-stock and make-to-order supply with low minimum order quantities, ensuring reliability and flexibility.
Reported Earnings • Oct 24Third quarter 2025 earnings released: EPS: US$1.94 (vs US$1.87 in 3Q 2024)Third quarter 2025 results: EPS: US$1.94 (up from US$1.87 in 3Q 2024). Revenue: US$804.6m (up 7.7% from 3Q 2024). Net income: US$140.0m (up 2.9% from 3Q 2024). Profit margin: 17% (in line with 3Q 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 23+ 1 more updateWest Pharmaceutical Services, Inc. Revises Earnings Guidance for the Full-Year 2025West Pharmaceutical Services, Inc. revised earnings guidance for the Full-Year 2025. For the year, the Company is increasing net sales guidance range to $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion. Reported net sales growth anticipated to be in the range of 5.8% to 6.1%, organic net sales growth is expected to be in the range of 3.75% to 4.0%, up from the previous guidance range of 3.0% to 3.75%. Net sales guidance includes an estimated benefit of approximately $59 million based on current foreign currency exchange rates. Diluted EPS is expected to be $6.75 to $6.80.
お知らせ • Oct 09West Pharmaceutical Services, Inc. to Report Q3, 2025 Results on Oct 23, 2025West Pharmaceutical Services, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025
New Risk • Sep 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Board Change • Sep 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 12West Pharmaceutical Services, Inc. Announces Departure of Kimberly Banks Mackay, Senior Vice President, General Counsel, and Corporate Secretary, Effective No Later Than December 31, 2025On September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure continuity and a smooth and orderly transition of responsibilities. Ms. MacKay will continue her current duties until she leaves the Company. The Company extends its gratitude to Ms. MacKay for her exemplary service and contributions during her tenure and wishes her success in her future endeavors.
Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 27Second quarter 2025 earnings released: EPS: US$1.83 (vs US$1.53 in 2Q 2024)Second quarter 2025 results: EPS: US$1.83 (up from US$1.53 in 2Q 2024). Revenue: US$766.5m (up 9.2% from 2Q 2024). Net income: US$131.8m (up 18% from 2Q 2024). Profit margin: 17% (up from 16% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €227, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €235 per share.
お知らせ • Jul 24+ 1 more updateWest Pharmaceutical Services, Inc. Increases Earnings Guidance for the Year 2025West Pharmaceutical Services, Inc. increased earnings guidance for the year 2025. The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%. Diluted EPS is expected to be $6.36 to $6.56.
お知らせ • Jul 22West Pharmaceutical Services, Inc. Announces Appointment of Robert McMahon as Senior Vice President, Effective as of August 4, 2025On July 21, 2025, West Pharmaceutical Services, Inc. Announced the appointment of Robert McMahon as Senior Vice President, effective as of August 4, 2025 (the “Commencement Date”). Mr. McMahon will serve on the Company's senior leadership team and will oversee finance, audit, treasury, tax, investor relations and procurement. Prior to joining West, Mr. McMahon, age 56, served as the Chief Financial Officer of Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. At Agilent, he was responsible for finance, audit, treasury, tax, investor relations, IT and procurement. From 2014 to 2018, Mr. McMahon served as Chief Financial Officer at Hologic, Inc., a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products. Prior to Hologic, Mr. McMahon spent 20 years with Johnson & Johnson in various executive financial roles of increasing responsibility. He has also served as an Independent Director at OraSure Technologies, Inc. since 2023. Mr. McMahon earned his Master of Business Administration from the University of Central Florida and his Bachelor's degree from the University of Florida.
お知らせ • Jul 21West Pharmaceutical Services, Inc. Announces CFO Changes, Effective August 4, 2025West Pharmaceutical Services, Inc. announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. Mr. McMahon has been Chief Financial Officer of Agilent Technologies Inc. since 2018. In this role, he is responsible for finance, audit, treasury, tax, investor relations, IT and procurement. Prior to Agilent, Mr. McMahon was the CFO at Hologic, Inc. and spent 20 years with Johnson & Johnson, in executive financial roles of increasing responsibility. He has also served as an Independent Director at OraSure Technologies, Inc. since 2023.
お知らせ • Jul 08West Pharmaceutical Services, Inc. to Report Q2, 2025 Results on Jul 24, 2025West Pharmaceutical Services, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 24, 2025
お知らせ • Jun 30+ 4 more updatesWest Pharmaceutical Services, Inc.(NYSE:WST) dropped from Russell 1000 Growth-Defensive IndexWest Pharmaceutical Services, Inc.(NYSE:WST) dropped from Russell 1000 Growth-Defensive Index